Kevin Mills - Cyteir Therapeutics CoFounder
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
Insider
Kevin Mills is CoFounder of Cyteir Therapeutics
| Phone | 857 285 4140 |
| Web | https://cyteir.com |
Kevin Mills Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kevin Mills against Cyteir Therapeutics stock is an integral part of due diligence when investing in Cyteir Therapeutics. Kevin Mills insider activity provides valuable insight into whether Cyteir Therapeutics is net buyers or sellers over its current business cycle. Note, Cyteir Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cyteir Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kevin Mills over three months ago Disposition of 55000 shares by Kevin Mills of Socket Mobile subject to Rule 16b-3 | ||
Kevin Mills over three months ago Acquisition by Kevin Mills of 2000 shares of Socket Mobile at 1.3674 subject to Rule 16b-3 | ||
Kevin Mills over three months ago Disposition of 45000 shares by Kevin Mills of Socket Mobile subject to Rule 16b-3 | ||
Kevin Mills over three months ago Acquisition by Kevin Mills of 157200 shares of Socket Mobile at 1.1197 subject to Rule 16b-3 |
Cyteir Therapeutics Management Efficiency
The company has Return on Asset of (0.145) % which means that on every $100 spent on assets, it lost $0.145. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2381) %, meaning that it generated no profit with money invested by stockholders. Cyteir Therapeutics' management efficiency ratios could be used to measure how well Cyteir Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cyteir Therapeutics has 889 K in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Cyteir Therapeutics has a current ratio of 19.55, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Cyteir to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Bazemore | Nuvation Bio | 53 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Gerald Md | Foghorn Therapeutics | N/A | |
| Michael MBA | Champions Oncology | N/A | |
| MS MBA | Generation Bio Co | 46 | |
| Jason CPA | MediciNova | 46 | |
| MD MBA | Rezolute | N/A | |
| Brian MD | Rezolute | 49 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| James Trager | Nkarta Inc | 61 | |
| Gary Lee | Lyell Immunopharma | 47 | |
| Crystal MD | Lyell Immunopharma | 63 | |
| MD MPH | MediciNova | 56 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Esq JD | Generation Bio Co | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Bernard JD | Sana Biotechnology | 69 | |
| Richard MD | Lyell Immunopharma | 72 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 |
Cyteir Therapeutics Leadership Team
Elected by the shareholders, the Cyteir Therapeutics' board of directors comprises two types of representatives: Cyteir Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyteir. The board's role is to monitor Cyteir Therapeutics' management team and ensure that shareholders' interests are well served. Cyteir Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyteir Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Esq, G Counsel | ||
| Markus MD, CEO President | ||
| Paul Secrist, Chief Officer | ||
| Gale Cohen, VP HR | ||
| Lisa Hayes, VP Communications | ||
| Joseph Zakrzewski, Independent Chairman | ||
| Timothy Romberger, Independent Director | ||
| Andrew Gengos, Chief Sec | ||
| Kevin Mills, CoFounder | ||
| David Gaiero, CFO Treasurer |
Cyteir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyteir Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |